IL-1β and TNFα-initiated IL-6-STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis.
暂无分享,去创建一个
A. Yoshimura | Y. Toyama | H. Yoshida | T. Miyamoto | K. Chiba | Takashi Kobayashi | M. Kawasumi | Tomoaki Mori | H. Morioka | M. Asakawa
[1] John J. O’Shea,et al. Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550) , 2011, The Journal of Immunology.
[2] T. Hirano,et al. Local microbleeding facilitates IL-6– and IL-17–dependent arthritis in the absence of tissue antigen recognition by activated T cells , 2011, The Journal of experimental medicine.
[3] M. Kubo,et al. Effects of a Janus kinase inhibitor, pyridone 6, on airway responses in a murine model of asthma. , 2011, Biochemical and biophysical research communications.
[4] D. Morris,et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis , 2010, Journal of Inflammation.
[5] J. Bland,et al. META060 inhibits osteoclastogenesis and matrix metalloproteinases in vitro and reduces bone and cartilage degradation in a mouse model of rheumatoid arthritis. , 2010, Arthritis and rheumatism.
[6] J. Fridman,et al. Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050 , 2010, The Journal of Immunology.
[7] Hong Ma,et al. STAT3 is a substrate of SYK tyrosine kinase in B-lineage leukemia/lymphoma cells exposed to oxidative stress , 2010, Proceedings of the National Academy of Sciences.
[8] F. Breedveld,et al. Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial , 2009, Annals of the rheumatic diseases.
[9] J. Pike,et al. A novel distal enhancer mediates cytokine induction of mouse RANKl gene expression. , 2009, Molecular endocrinology.
[10] I. McInnes,et al. Animal models of rheumatoid arthritis , 2009, European journal of immunology.
[11] H. Aburatani,et al. BMP2 Regulates Osterix through Msx2 and Runx2 during Osteoblast Differentiation* , 2008, Journal of Biological Chemistry.
[12] Toshio Hirano,et al. Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction. , 2008, Immunity.
[13] L. Audoly,et al. Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis , 2008, Arthritis research & therapy.
[14] A. Brasier,et al. The Functional Role of an Interleukin 6-inducible CDK9·STAT3 Complex in Human γ-Fibrinogen Gene Expression* , 2007, Journal of Biological Chemistry.
[15] Katsuaki Sato,et al. Selective Expansion of Foxp3-Positive Regulatory T Cells and Immunosuppression by Suppressors of Cytokine Signaling 3-Deficient Dendritic Cells1 , 2007, The Journal of Immunology.
[16] P. Emery,et al. Long-term infliximab treatment in rheumatoid arthritis: subsequent outcome of initial responders. , 2007, Rheumatology.
[17] Chen Dong,et al. STAT3 Regulates Cytokine-mediated Generation of Inflammatory Helper T Cells* , 2007, Journal of Biological Chemistry.
[18] Kozo Nakamura,et al. Impaired bone fracture healing in matrix metalloproteinase-13 deficient mice. , 2007, Biochemical and biophysical research communications.
[19] R. D. Hatton,et al. Transforming growth factor-β induces development of the TH17 lineage , 2006, Nature.
[20] P. Miller,et al. Denosumab in Postmenopausal Women with Low Bone Mineral Density , 2007 .
[21] Y. Toyama,et al. DC-STAMP is essential for cell–cell fusion in osteoclasts and foreign body giant cells , 2005, The Journal of experimental medicine.
[22] T. Kishimoto. Interleukin-6: from basic science to medicine--40 years in immunology. , 2005, Annual review of immunology.
[23] T. Mcclanahan,et al. Divergent Pro- and Antiinflammatory Roles for IL-23 and IL-12 in Joint Autoimmune Inflammation , 2003, The Journal of experimental medicine.
[24] J. O’Shea,et al. Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor , 2003, Science.
[25] R. Kitazawa,et al. Vitamin D3 supports osteoclastogenesis via functional vitamin D response element of human RANKL gene promoter , 2003, Journal of cellular biochemistry.
[26] R. Price,et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. , 2002, Arthritis and rheumatism.
[27] Lionel B Ivashkiv,et al. Rheumatoid Arthritis Synoviocyte Survival Is Dependent on Stat31 , 2002, The Journal of Immunology.
[28] Y. Saeki,et al. A Point Mutation of Tyr-759 in Interleukin 6 Family Cytokine Receptor Subunit gp130 Causes Autoimmune Arthritis , 2002, The Journal of experimental medicine.
[29] Takafumi Yoshida,et al. Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis. , 2001, The Journal of clinical investigation.
[30] D. Männel,et al. A Novel p75TNF Receptor Isoform Mediating NFκB Activation* , 2001, The Journal of Biological Chemistry.
[31] Y. Toyama,et al. Macrophage- and neutrophil- dominant arthritis in human IL-1α transgenic mice , 2001 .
[32] G. Stark,et al. IL-1-induced NFκB and c-Jun N-terminal kinase (JNK) activation diverge at IL-1 receptor-associated kinase (IRAK) , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[33] T. Suda,et al. An adherent condition is required for formation of multinuclear osteoclasts in the presence of macrophage colony-stimulating factor and receptor activator of nuclear factor κB ligand , 2000 .
[34] K. Hirokawa,et al. Adenoviral Transfer of Cyclin-Dependent Kinase Inhibitor Genes Suppresses Collagen-Induced Arthritis in Mice1 , 2000, The Journal of Immunology.
[35] H. Genant,et al. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. , 2000, Arthritis and rheumatism.
[36] S. Morham,et al. Prostaglandin G/H synthase-2 is required for maximal formation of osteoclast-like cells in culture. , 2000, The Journal of clinical investigation.
[37] C. O’Brien,et al. STAT3 Activation in Stromal/Osteoblastic Cells Is Required for Induction of the Receptor Activator of NF-κB Ligand and Stimulation of Osteoclastogenesis by gp130-utilizing Cytokines or Interleukin-1 but Not 1,25-Dihydroxyvitamin D3 or Parathyroid Hormone* , 1999, The Journal of Biological Chemistry.
[38] S. Morony,et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis , 1999, Nature.
[39] K Yano,et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[40] C. Gabay,et al. Interleukin-1 receptor antagonist: role in biology. , 1998, Annual review of immunology.
[41] J. Darnell. STATs and gene regulation. , 1997, Science.
[42] S. Akira,et al. Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[43] E. Sercarz,et al. Inactivation of T cell receptor peptide-specific CD4 regulatory T cells induces chronic experimental autoimmune encephalomyelitis (EAE) , 1996, The Journal of experimental medicine.
[44] J. Woody,et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis , 1994, The Lancet.
[45] D. Kioussis,et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. , 1991, The EMBO journal.
[46] D. Woolley,et al. Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint. , 1984, Arthritis and rheumatism.
[47] M. Dallman,et al. Immunisation against heterologous type II collagen induces arthritis in mice , 1980, Nature.
[48] A. Kang,et al. Autoimmunity to type II collagen an experimental model of arthritis , 1977, The Journal of experimental medicine.